CERSCERUS CORP
Surgical & Medical Instruments & Apparatus
- Revenue
- $234M
- 16% YoY
- Operating margin
- -3.7%
- 47% YoY
- EBITDA
- −$7M
- 41% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $2M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear10% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear1% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $160M | $188M | $187M | $201M | $234M | 16% |
| Operating income | −$49M | −$34M | −$30M | −$14M | −$9M | 39% |
| Net income | −$54M | −$43M | −$37M | −$21M | −$16M | 25% |
| Operating cash flow | −$34M | −$26M | −$43M | $11M | $5M | 57% |
| Capex | $910K | $2M | $5M | $3M | $4M | 31% |
| Stock-based comp | $24M | $24M | $20M | $23M | $23M | 0.0% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $4M | $6M | 30 | 68 |
| FY2024 | $3M | $2M | 22 | 76 |
| FY2023 | $4M | $760K | 31 | 83 |
| FY2022 | $5M | $120K | 53 | 79 |
| FY2021 | $5M | $5M | 98 | 120 |